NCT03639480

Study to Evaluate the Safety and Efficacy of CJ-30061 in Hypertensive Patients With Hyperlipidemia

A Double-blind, Randomized, Multi-center Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of CJ-30061 Compared With Amlodipine/Valsartan Combination Therapy and Valsartan/Atorvastatin Combination Therapy in Hypertensive Patients With Hyperlipidemia

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 180 (estimated)
• Sponsor: HK inno.N Corporation · Industry
• Sex: All
• Age: 19 Years – 74 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety and efficacy of CJ-30061 compared with amlodipine/valsartan combination therapy and valsartan/atorvastatin combination therapy in hypertensive patients with hyperlipidemia

Conditions

• Hypertension
• Hyperlipidemia

Interventions

Type	Name	Description
DRUG	Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg	Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
DRUG	Amlodipine 10mg+Valsartan 160mg	Amlodipine 10mg+Valsartan 160mg
DRUG	Valsartan 160mg+Atorvastatin 40mg	Valsartan 160mg+Atorvastatin 40mg

Timeline

• Start date: 2017-10-13
• Primary completion: 2018-10-01
• Completion: 2018-10-01
• First posted: 2018-08-21
• Last updated: 2018-08-21

Locations

1 site across 1 country: South Korea